丙酸睾酮/庚酸睾酮/十一烯酸睾酮

**丙酸睾酮/庚酸睾酮/十一烯酸睾酮**
组成
丙酸睾酮	雄激素、合成代谢类固醇
庚酸睾酮	雄激素、合成代谢类固醇
十一烯酸睾酮	雄激素、合成代谢类固醇
臨床資料
商品名	Durasteron
其他名稱	TP/TE/TUe
给药途径	肌肉注射

丙酸睾酮/庚酸睾酮/十一烯酸睾酮，简称TP/TE/TUe，以商品名Durasteron出售，是丙酸睾酮（TP）、庚酸睾酮（TV）和十一烯酸睾酮（TUe）的注射复方药，它们都是雄激素/合成代谢类固醇。[1][2]它是一种油溶液，含有20毫克TP、80毫克TE和150毫克TUe（总共250毫克睾酮酯和169.5毫克游离睾酮），并通过定期肌肉注射给药，例如每3或4周一次。[3][4][5]据报道，部分健美运动员使用Durasteron。[1][2]

参见

丙酸睾酮/戊酸睾酮/十一烯酸睾酮
性激素复方制剂列表

参考资料

Daher EF, Silva Júnior GB, Queiroz AL, Ramos LM, Santos SQ, Barreto DM, et al. . International Urology and Nephrology. 2009, 41 (3): 717–23. PMID 19387860. S2CID 23319246. doi:10.1007/s11255-009-9571-8.
Davani-Davari D, Karimzadeh I, Khalili H. . BMC Nephrology. May 2019, 20 (1): 198. PMC 6545019 . PMID 31151420. doi:10.1186/s12882-019-1384-0 .
Joël, Charles A. [For the treatment of male fertility disorders with high androgen doses]. Gynecologic and Obstetric Investigation. 1960, 150 (3): 149–156. ISSN 1423-002X. doi:10.1159/000305737. [...] 20 mg Testosteronpropionat, 80 mg Testosteronheptanoat, 150 mg Testosteronundecylat (Durasteron Teva) [...]
Arends G, Zörnig H, Hager H, Frerichs G, Kern W. . Springer-Verlag. 14 December 2013: 1145–. ISBN 978-3-662-36329-4. At the same time, treatment with a long-acting testosterone preparation (Durasteron®) was instituted, with one injection given every four weeks.
Spitz IM, Hirsch HJ, Landau H, Zylber-Haran E, Gross V, Rachmilewitz EA. . Journal of Endocrinological Investigation. October 1984, 7 (5): 495–9. PMID 6439771. S2CID 20319052. doi:10.1007/BF03348456. The male patients were given a long acting tes- tosterone preparation (Durasteron, Teva) 250 mg by im injection every 3 weeks for a total of 8 injections.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[DaherSilva_Júnior2009-1] Daher EF, Silva Júnior GB, Queiroz AL, Ramos LM, Santos SQ, Barreto DM, et al. . International Urology and Nephrology. 2009, 41 (3): 717–23. PMID 19387860. S2CID 23319246. doi:10.1007/s11255-009-9571-8.

[Davani-DavariKarimzadeh2019-2] Davani-Davari D, Karimzadeh I, Khalili H. . BMC Nephrology. May 2019, 20 (1): 198. PMC 6545019 . PMID 31151420. doi:10.1186/s12882-019-1384-0 .

[Joël1960-3] Joël, Charles A. [For the treatment of male fertility disorders with high androgen doses]. Gynecologic and Obstetric Investigation. 1960, 150 (3): 149–156. ISSN 1423-002X. doi:10.1159/000305737. [...] 20 mg Testosteronpropionat, 80 mg Testosteronheptanoat, 150 mg Testosteronundecylat (Durasteron Teva) [...]

[ArendsZörnig2013-4] Arends G, Zörnig H, Hager H, Frerichs G, Kern W. . Springer-Verlag. 14 December 2013: 1145–. ISBN 978-3-662-36329-4. At the same time, treatment with a long-acting testosterone preparation (Durasteron®) was instituted, with one injection given every four weeks.

[SpitzHirsch2014-5] Spitz IM, Hirsch HJ, Landau H, Zylber-Haran E, Gross V, Rachmilewitz EA. . Journal of Endocrinological Investigation. October 1984, 7 (5): 495–9. PMID 6439771. S2CID 20319052. doi:10.1007/BF03348456. The male patients were given a long acting tes- tosterone preparation (Durasteron, Teva) 250 mg by im injection every 3 weeks for a total of 8 injections.